SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithKline Consumer Healthcare rises on inking pact with GSK Pharmaceuticals

07 May 2013 Evaluate

Glaxosmithkline Consumer Healthcare is currently trading at Rs. 4053.00, up by 11.40 points or 0.28 % from its previous closing of Rs. 4041.60 on the BSE.

The scrip opened at Rs. 4035.00 and has touched a high and low of Rs. 4080.10 and Rs. 4025.10 respectively.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4334.00 on 22-Feb-2013 and a 52 week low of Rs. 2179.00 on 18-Jul-2012.

Last one week high and low of the scrip stood at Rs. 4260.00 and Rs. 3810.05 respectively. The current market cap of the company is Rs. 17074.55 crore.

The promoters holding in the company stood at 72.46% while Institutions and Non-Institutions held 11.86% and 15.69% respectively.

GlaxoSmithKline Consumer Healthcare has signed a brandsswap deal with its associate company GSK Pharmaceuticals, in order to cross Rs 8,000-crore revenue mark by 2016. With this brandsswap deal, the entity can select brands and independently market, sell and distribute them. With this initiative, both the firms can increase distribution pooling in their resources.

Initially, it will market and sell GSK Pharma's over-the counter calcium and vitamin supplement Ostocalcium while GSK Pharma will market and distribute products under the consumer division’s specialized arm Glaxo Nutrition including Actibase and Actigrow nutrition supplements. The deals will involve a cost that both the listed entities will pay each other.

Glaxo.Cons. Health Share Price

9696.40 0.00 (0.00%)
15-Apr-2020 18:01 View Price Chart
Peers
Company Name CMP
Varun Beverages 466.70
Nestle 1285.15
Britannia Inds 5684.30
LT Foods 416.40
Hatsun Agro Product 977.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×